If selection criteria are to be based on the risk of cancer recurrence for HR+/HER2-negative eBC patients, GT for BRCA germline pathogenic variants should be offered to patients who are assessed to be at high risk of cancer recurrence irrespective of age at cancer diagnosis or family history. This evidence concerns the gene ERBB2 and cancer.